<DOC>
	<DOCNO>NCT01916135</DOCNO>
	<brief_summary>This study first time new experimental drug call [ 18F ] -SKI-249380 use people . [ 18F ] -SKI-249380 therapeutic drug . [ 18F ] -SKI-249380 drug use PET scanner 'see ' [ 18F ] -SKI-249380 go body , inject . The researcher believe scan [ 18F ] -SKI-249380 might able find tumors patient . This study do see long [ 18F ] -SKI-249380 stay blood , give people tiny amount injection vein arm , see [ 18F ] -SKI-249380 go body . If result trial good , study doctor plan use [ 18F ] -SKI-249380 another trial see scan [ 18F ] -SKI-249380 well find tumor compare standard type scan doctor use .</brief_summary>
	<brief_title>PET Imaging Cancer Patients Using 18F-SKI-249380 , Radiolabeled Dasatinib-Derivative</brief_title>
	<detailed_description />
	<mesh_term>Dasatinib</mesh_term>
	<criteria>Patients history histologicallyconfirmed neoplasm follow classification : solid malignancy , myeloid neoplasm , lymphoid neoplasm . Histology confirm MSKCC Department Pathology . Disease either : Radiologicallymeasurable evaluable define tumor response criterion MSKCCIRB approve clinic research protocol . Detectable biopsy ( eg , bone marrow ) and/or peripheral blood assay obtain within 6 week study enrollment Age 2190 Negative serum pregnancy test female childbearing age ( 1155 year ) potential ( ie , woman postmenopausal start ongoing treatment , applicable ; surgical intervention whose intent effect sterilization , tubal ligation hysterectomy . ) Not breastfeed , applicable . Refusal inability discontinue medication substance ( eg , food dietary supplement ) may affect [ 18F ] SKI249380 metabolism . Notably , dasatinib metabolism CYP3A4dependent , metabolism [ 18F ] SKI249380 may alter inhibitor inducer cytochrome P450 isoenzyme CYP3A4 . The acceptability medication substance use patient determine study investigator . Inability refusal least one peripheral intravenous line intravenous access ( applicable day [ 18F ] SKI249380 injection blood draw . ) Refusal inability tolerate scanning procedure ( e.g. , due claustrophobia ) Hepatic : assay obtain &lt; 2 week prior study enrollment Bilirubin &gt; 1.5 x institutional upper limit normal ( ULN ) AST/ALT &gt; 2.5 x ULN Albumin &lt; 2 g/dl GGT &gt; 2.5 x ULN IF Alkaline phosphatase &gt; 2.5 x ULN . Renal : Creatinine &gt; 1.5 x ULN creatinine clearance &lt; 60 mL/min , assay obtain &lt; 2 week prior study enrollment Acute major illness ( e.g. , unstable cardiovascular condition , etc . )</criteria>
	<gender>All</gender>
	<minimum_age>21 Years</minimum_age>
	<maximum_age>90 Years</maximum_age>
	<verification_date>October 2016</verification_date>
	<keyword>[ 18F ] -SKI-249380</keyword>
	<keyword>PET Imaging</keyword>
	<keyword>CT Imaging</keyword>
	<keyword>12-182</keyword>
</DOC>